Form 13-F position report

NUVALENT INC

Reported by Bain Capital Life Sciences Investors LLC

Company profile Manager portfolio Source filing
NUVL CUSIP 670703107 Manager CIK 0001703031
Latest reported change

Reported 0 shares, down 1,447,267 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q3 2025
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 17 Through Q3 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

17 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q3 2025 Reduced 0 -1,447,267 (-100.0%) 0 $0 2025-11-14
Q2 2025 Unchanged 1,447,267 0 (0.0%) 13.82% $110,426,472 2025-08-14
Q1 2025 Unchanged 1,447,267 0 (0.0%) 15.19% $102,640,176 2025-05-15
Q4 2024 Reduced 1,447,267 -1,250,000 (-46.3%) 13.33% $113,292,061 2025-02-14
Q3 2024 Unchanged 2,697,267 0 (0.0%) 28.71% $275,930,414 2024-11-14
Q2 2024 Unchanged 2,697,267 0 (0.0%) 22.46% $204,614,675 2024-08-12
Q1 2024 Reduced 2,697,267 -880,000 (-24.6%) 16.28% $202,537,779 2024-05-15
Q4 2023 Unchanged 3,577,267 0 (0.0%) 25.23% $263,251,079 2024-02-13
Q3 2023 Unchanged 3,577,267 0 (0.0%) 18.39% $164,446,964 2023-11-14
Q2 2023 Unchanged 3,577,267 0 (0.0%) 15.54% $150,853,349 2023-08-14
Q1 2023 Unchanged 3,577,267 0 (0.0%) 11.66% $93,331,000 2023-05-15
Q4 2022 Added 3,577,267 +149,253 (4.4%) 11.9% $106,531,000 2023-02-14
Q3 2022 Unchanged 3,428,014 0 (0.0%) 7.95% $66,641,000 2022-11-14
Q2 2022 Unchanged 3,428,014 0 (0.0%) 5.45% $46,484,000 2022-08-15
Q1 2022 Unchanged 3,428,014 0 (0.0%) 4.62% $47,615,000 2022-05-16
Q4 2021 Unchanged 3,428,014 0 (0.0%) 5.18% $65,269,000 2022-02-14
Q3 2021 New 3,428,014 +3,428,014 (0.0%) 4.8% $77,302,000 2021-11-15
Institutional context

Who else reported the position

233 managers reported NUVALENT INC for Q3 2025.

Manager Activity Shares Change % of reported 13F Reported value Tenure
DEERFIELD MANAGEMENT COMPANY L P SERIES C Unchanged 17,991,024 0 23.75% $1,555,863,756 17 qtrs
FMR LLC Added 10,013,237 +44,391 0.05% $865,944,758 17 qtrs
Paradigm Biocapital Advisors LP Unchanged 5,269,433 0 12.96% $455,700,566 10 qtrs
VANGUARD GROUP INC Added 4,605,007 +80,883 < 0.01% $398,241,005 17 qtrs
BlackRock Inc Added 4,085,795 +39,539 < 0.01% $353,339,552 5 qtrs
WELLINGTON MANAGEMENT GROUP LLP Added 2,300,865 +724,491 0.03% $198,978,805 17 qtrs
JANUS HENDERSON GROUP PLC Added 2,188,674 +406,093 0.09% $189,340,492 17 qtrs
PRICE T ROWE ASSOCIATES INC MD Added 1,810,420 +15,047 0.02% $156,566,000 12 qtrs
JPMorgan Chase & Co Added 1,674,009 +476,822 < 0.01% $144,768,373 17 qtrs
STATE STREET CORPORATION Added 1,574,747 +84,468 < 0.01% $136,184,121 17 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2025
Filed
November 14, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.